Expert Review of Vaccines最新文献_第5页

Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. 18月龄时血清型特异性血清免疫球蛋白G：一项随机对照研究：接种一剂或两剂10价或13价肺炎球菌结合疫苗的初级系列，并在9月龄时接种加强剂。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/14760584.2025.2458179

Alane Izu, Eleanora Aml Mutsaerts, Courtney Olwagen, Lisa Jose, Anthonet Koen, Amit J Nana, Clare L Cutland, Shabir A Madhi

{"title":"Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study.","authors":"Alane Izu, Eleanora Aml Mutsaerts, Courtney Olwagen, Lisa Jose, Anthonet Koen, Amit J Nana, Clare L Cutland, Shabir A Madhi","doi":"10.1080/14760584.2025.2458179","DOIUrl":"10.1080/14760584.2025.2458179","url":null,"abstract":"Background: Due to high costs of pneumococcal conjugate vaccines (PCV), transitioning from a two (2 + 1) to a single dose (1 + 1) primary series with a booster should be considered. This study evaluated the immune response at 18 months of age following a 1 + 1 compared to a 2 + 1 schedule of 10-valent (PCV10) and 13-valent (PCV13) vaccines.Research design and methods: A single-center, open-label, randomized trial conducted in Soweto, South Africa, evaluated the immunogenicity of differing dosing schedule for PCV10 and PCV13. Six hundred children were randomly assigned to six study arms (1:1:1:1:1:1). Non-inferiority was concluded when the lower limit of the 96% confidence interval of the ratio of geometric mean concentrations (GMCs) of the 1 + 1 and 2 + 1 schedules was >0.5 for at least 10 and eight of the PCV13 and PCV10 serotypes, respectively.Results: GMCs in children who received the PCV13_6w + 1 and PCV13_14w + 1 schedule were non-inferior for 11 and 10 of the PCV13 serotypes, respectively, compared with the PCV13_2 + 1 arm. For PCV10, GMCs for both 1 + 1 schedules were non-inferior to a 2 + 1 schedule for nine of the PCV10 serotypes.Conclusion: Transitioning to a 1 + 1 schedule should be considered for early immunization programs.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02943902.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"121-127"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patterns of co-administration and sequential administration of COVID-19 and influenza vaccinations: a US study using Adheris pharmacy dataset. COVID-19和流感疫苗的联合给药和顺序给药模式：一项使用黏贴药房数据集的美国研究

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-21 DOI: 10.1080/14760584.2025.2505766

Alon Yehoshua, Tianyan Hu, Taryn Pond, Jingyan Yang, Verna Welch, Constantina Boikos, Sen Deng, Hao Zheng, Poorva Sardana, Neha Agrawal, Manvi Sharma

{"title":"Patterns of co-administration and sequential administration of COVID-19 and influenza vaccinations: a US study using Adheris pharmacy dataset.","authors":"Alon Yehoshua, Tianyan Hu, Taryn Pond, Jingyan Yang, Verna Welch, Constantina Boikos, Sen Deng, Hao Zheng, Poorva Sardana, Neha Agrawal, Manvi Sharma","doi":"10.1080/14760584.2025.2505766","DOIUrl":"10.1080/14760584.2025.2505766","url":null,"abstract":"Background: This study assessed monthly patterns of co-administration of COVID-19 and influenza vaccines at visit level and quantified the number and proportion of adults who received both vaccines on the same day or sequentially.Research design and methods: This retrospective study utilized the Adheris pharmacy dataset and included adults aged ≥ 19 years with a record of ≥ 1 dose of COVID-19 or influenza vaccines between August 2022 and December 2023. Administration of both vaccines on the same day was defined as co-administration, and administration of vaccines within 1-180 days was referred to as sequential administration. Descriptive analyses were performed.Results: Among 31.5 million visits with either COVID-19 or influenza vaccines, 5.8 million (18.5%) involved co-administration. Co-administration visits were higher between September and November compared to other months, rising to 1.5 million in October 2023. Among 7.9 million adults with both vaccines, 65.8% had same day administration, while 34.2% had sequential administration. 60.7% of adults with sequential administration received the vaccines within 1-30 days.Conclusions: About one in five COVID-19 or influenza vaccinations involved co-administration. The majority of sequential administrations happened within 30 days, highlighting missed opportunities for co-administration. These findings suggest substantial potential to improve uptake of both vaccines through co-administration.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"433-443"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future. 欧洲老年人加强流感疫苗接种：对现状的审查和对未来的专家建议

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-09 DOI: 10.1080/14760584.2025.2499728

Gaëtan Gavazzi, Bertrand Fougère, Olivier Hanon, Isabel Leroux-Roels, Etienne Brochot, Elodie Blanchard, Colin A Russell, Marc Paccalin, Tino F Schwarz

{"title":"Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future.","authors":"Gaëtan Gavazzi, Bertrand Fougère, Olivier Hanon, Isabel Leroux-Roels, Etienne Brochot, Elodie Blanchard, Colin A Russell, Marc Paccalin, Tino F Schwarz","doi":"10.1080/14760584.2025.2499728","DOIUrl":"https://doi.org/10.1080/14760584.2025.2499728","url":null,"abstract":"Introduction: Influenza causes considerable morbidity and mortality in Europe, particularly among older adults due to comorbidities, as well as immunosenescence and inflammaging, which contribute to a diminished immune response. Vaccination remains the most effective way to prevent poor outcomes; however, uptake is suboptimal and many countries recommend standard vaccines despite evidence supporting better protection with enhanced (adjuvanted and high-dose) vaccines.Areas covered: A multidisciplinary group of experts reviewed the burden of influenza in Europe and evaluated data on enhanced vaccines, providing recommendations for their use in older adults. The group discussed barriers to vaccination and strategies to increase uptake.Expert opinion: Improving protection of older adults against influenza relies upon increasing vaccine uptake and ensuring access to vaccines that overcome age-related immunological decline. Achieving higher uptake requires national policies that facilitate equitable access and clear communication about vaccine eligibility. Based on available evidence, enhanced vaccines offer better protection than standard vaccines against hospitalization and complications in older adults. National recommendations should prioritize the use of enhanced influenza vaccines over standard vaccines in older adults. Limitations to interpretation of evidence include discrepancies in reporting of influenza-related medical encounters and underreporting of influenza-related complications.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"350-364"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice. 管制微生物疫苗：从概念到（临床前）减少到实践。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-02-03 DOI: 10.1080/14760584.2025.2459751

Richard Voellmy, David C Bloom, Nuria Vilaboa

{"title":"Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice.","authors":"Richard Voellmy, David C Bloom, Nuria Vilaboa","doi":"10.1080/14760584.2025.2459751","DOIUrl":"10.1080/14760584.2025.2459751","url":null,"abstract":"Introduction: Vaccines to prevent important infections involving, e.g. influenza viruses, severe acute respiratory syndrome-causing coronaviruses (e.g. SARS-CoV-2), respiratory syncytial viruses (RSV), and human immunodeficiency viruses (HIV) have remained insufficiently effective or are not available at all. Regulated microbes constitute novel vaccine platforms that may be employed for the development of more potent and/or more broadly effective vaccines.Areas covered: We review the development and characterization of the vaccine potential of replication-competent controlled herpesviruses (RCCVs) which represent the first examples of regulated microbes used as vaccines.Expert opinion: The RCCVs developed to date are suitable for application to the skin and can be activated deliberately to replicate efficiently, but only transiently, in the administration site. Without activation, the RCCVs are incapable of replicating in the nervous system and elsewhere. The RCCVs were found to induce potent anti-herpetic immune responses in mice. Vaccination with RCCVs expressing an influenza virus hemagglutinin broadly protected animals against lethal influenza virus challenges. This protection appeared to be at least in part antibody-mediated. These findings support a rational expectation that RCCVs may be developed into universal, non-seasonal vaccines against influenza and, possibly, against other rapidly evolving pathogens.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"146-156"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study. 自扩增mRNA SARS-CoV-2疫苗ARCT-154在成人中的安全性：一项合并1/2/3期随机临床研究

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-04-12 DOI: 10.1080/14760584.2025.2487542

Nhan Thi Ho, Igor Smolenov, Ly Thi Le Tran, Van Thu Nguyen, Van Thanh Ta, Thuong Vu Nguyen, Hung Ngoc Pham, Anh Thi Van Pham, Quang Chan Luong, Men Van Chu, Mai Thi Ngoc Dang, Toan Trong Nguyen, Vy Thi Tuong Le, Quang Vinh Trinh, Thang Van Nguyen, Anh Ngoc Nguyen, Ha Thai Pham, Giang Duc Dao, Carmen Baccarini, Ekpeno Nnah, Alia Hawkes, Suezanne Parker, Carole Verhoeven, Judd L Walson, Xuan-Hung Nguyen

{"title":"Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study.","authors":"Nhan Thi Ho, Igor Smolenov, Ly Thi Le Tran, Van Thu Nguyen, Van Thanh Ta, Thuong Vu Nguyen, Hung Ngoc Pham, Anh Thi Van Pham, Quang Chan Luong, Men Van Chu, Mai Thi Ngoc Dang, Toan Trong Nguyen, Vy Thi Tuong Le, Quang Vinh Trinh, Thang Van Nguyen, Anh Ngoc Nguyen, Ha Thai Pham, Giang Duc Dao, Carmen Baccarini, Ekpeno Nnah, Alia Hawkes, Suezanne Parker, Carole Verhoeven, Judd L Walson, Xuan-Hung Nguyen","doi":"10.1080/14760584.2025.2487542","DOIUrl":"10.1080/14760584.2025.2487542","url":null,"abstract":"Background: Public health concerns due to ongoing emergence of SARS-CoV-2 variants necessitates further development of improved COVID-19 vaccines. One major innovation are self-amplifying mRNA vaccines, such as ARCT-154 (Arcturus Therapeutics, Inc.), which induces superior immunogenicity compared with conventional mRNA in terms of magnitude, breadth and persistence of neutralizing antibodies.Research design and methods: In a pivotal placebo-controlled trial in Vietnam combining phase 1, 2 and 3 cohorts, over 17,000 adults received at least one dose of ARCT-154. Here, we report the safety and reactogenicity observations made.Results: ARCT-154 elicited more local reactions than the saline placebo, most reports of injection site pain were mild/moderate with only a few reporting severe pain. Most frequent solicited adverse events were fatigue, myalgia, headache, arthralgia and chills. Solicited local and systemic reactogenicity resolved within 7 days. Long-term follow-up has not revealed any safety concerns, with no reports of myocarditis or pericarditis. Acceptable tolerability of ARCT-154 was also observed in older participants and in those liable to severe consequences of COVID-19 due to underlying medical conditions. No serious consequences occurred in several pregnancies reported after vaccination, with normal outcomes when followed to term.Conclusions: Data from this large trial suggest that ARCT-154 is safe and well tolerated.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"299-312"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. SARS-CoV-2重组蛋白疫苗（CHO细胞）LYB001作为异源加强剂在2剂或3剂灭活COVID-19疫苗后对≥18岁成人的免疫原性和安全性：一项随机、主动对照、双盲、3期试验的中期结果

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-05 DOI: 10.1080/14760584.2024.2446288

Bei-Fang Yang, Jing Jin, Xi-Ran He, Zhong-Hua Yang, Xiao'ai Qian, Ye-Qing Tong, Chang-Xian Ke, Zhao-Hong Li, Zhao-Xia Li, Lin-Feng Zhong, Ze-Hong Gan, Xian-Feng Zhang, Ying Zeng

{"title":"Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.","authors":"Bei-Fang Yang, Jing Jin, Xi-Ran He, Zhong-Hua Yang, Xiao'ai Qian, Ye-Qing Tong, Chang-Xian Ke, Zhao-Hong Li, Zhao-Xia Li, Lin-Feng Zhong, Ze-Hong Gan, Xian-Feng Zhang, Ying Zeng","doi":"10.1080/14760584.2024.2446288","DOIUrl":"10.1080/14760584.2024.2446288","url":null,"abstract":"Background: LYB001 is a recombinant protein COVID-19 vaccine displaying a receptor-binding domain (RBD) in a highly immunogenic array on virus-like particles (VLPs). This study assessed the immunogenicity and safety of LYB001 as a booster.Research design and methods: In this randomized, active-controlled, double-blinded, phase 3 trial, participants aged ≥ 18 years received a booster with LYB001 or ZF2001 (Recombinant COVID-19 Vaccine). The primary endpoint was to compare the geometric mean titer (GMT) of neutralizing antibodies against Omicron BA.4/5 at 14 days after the booster.Results: Overall, 1,200 participants aged ≥ 18 years were enrolled, 599 received LYB001, and 601 received ZF2001. Based on similar baseline level, the 14-day GMT ratio (LYB001/ZF2001) against Omicron BA.4/5 was 1.39 (95% CI: 1.25, 1.56), demonstrating superiority (95% CI lower limit > 1) of LYB001. The spike protein-binding IgG concentrations induced by LYB001 were significantly higher than those induced by ZF2001 on day 14 and day 28 after the booster (p-value <0.0001). LYB001 recipients reported more adverse reactions than ZF2001 recipients (21.4% vs. 15.0%); however, all adverse reactions in the LYB001 group were mild-to-moderate.Conclusions: LYB001 is highly immunogenic and retains a well-characterized safety profile in adults aged ≥ 18 years.Clinical trial registration: www.clinicaltrials.gov, identifier is NCT05664932.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"81-90"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome. 值得一走的旅程：全球根除麻疹、风疹和先天性风疹综合征。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-08 DOI: 10.1080/14760584.2025.2476535

Jon Kim Andrus, David N Durrheim

引用次数: 0

Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review. HIV感染者接种乙肝疫苗时使用HepB-CpG：一项叙述性综述

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-12 DOI: 10.1080/14760584.2025.2502643

Kelvin McKoy, Stephanie Campbell, Patricia Novy, Robert S Janssen

{"title":"Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review.","authors":"Kelvin McKoy, Stephanie Campbell, Patricia Novy, Robert S Janssen","doi":"10.1080/14760584.2025.2502643","DOIUrl":"10.1080/14760584.2025.2502643","url":null,"abstract":"Introduction: To eliminate hepatitis B virus (HBV) globally, a key focus is preventing new infections among high-risk individuals, including those with HIV. The widespread incidence of HBV and HIV leads to a high rate of coinfection. HIV compromises the immune system, significantly increasing the risk of chronic HBV infection, cirrhosis, liver cancer, and death from liver-related disease among coinfected individuals.Areas covered: This review explores recent research on the two-dose HepB-CpG (HEPLISAV-B) vaccine, which is a potential solution to the challenge of suboptimal immune responses to three-dose HBV vaccines (HepB-alum) in people living with HIV (PLWH). We compare the immunogenicity and safety of HepB-CpG in both vaccine-naive and previously vaccinated nonresponding PLWH populations.Expert opinion: Compared with three-dose HepB-alum vaccines, HepB-CpG offers a more convenient two-dose schedule, which could increase series completion rates. HepB-CpG might be more immunogenic in vaccine-naive and vaccine-experienced PLWH. Both attributes make HepB-CpG a possible future standard of care for adult HBV vaccination in PLWH.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"365-372"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis. 中国9-16岁女孩接种人乳头瘤病毒疫苗的成本效益：一项荟萃分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-13 DOI: 10.1080/14760584.2025.2517715

Xiaoya Fu, Yilan Xia, Weiyu Zhou, Yihan Lu

{"title":"Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis.","authors":"Xiaoya Fu, Yilan Xia, Weiyu Zhou, Yihan Lu","doi":"10.1080/14760584.2025.2517715","DOIUrl":"10.1080/14760584.2025.2517715","url":null,"abstract":"Introduction: Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.Methods: We searched PubMed, Embase®, Web of Science, and Cochrane databases from inception to 18 January 2024, for cost-effectiveness analyses of 2vHPV, 4vHPV, and 9vHPV vaccines compared to no HPV vaccination (NoV) and to each other. All monetary units were adjusted to 2022 US dollars. INBs were calculated as the difference in incremental effectiveness multiplied by the willingness-to-pay threshold minus the incremental cost and pooled by vaccine type using random-effects or fixed-effects models.Results: Sixteen studies involving 61 comparisons were included. The INBs (95% CI) for domestic 2vHPV, imported 2vHPV, 4vHPV, and 9vHPV vaccines, compared to NoV, were USD 569.99 (58.62, 1081.36), 186.39 (86.21, 286.57), 239.14 (142.46, 335.81), and 298.41 (198.31, 398.51), respectively. HPV vaccines were significantly cost-effective compared to NoV. 4vHPV vaccine was less cost-effective than imported 2vHPV vaccine, with an INB of USD - 693.98 (-1062.17, -325.79).Conclusions: HPV vaccines were cost-effective compared to NoV in China. Our findings would facilitate policy-making of HPV immunization programs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"524-534"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia. RSVPreF3佐剂疫苗对60岁及以上成年人的潜在公共卫生影响：来自印度和东南亚的一项模拟研究的结果

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-06-20 DOI: 10.1080/14760584.2025.2523602

Ru Han, Ja Gomez, Cn Quy, Otavio Cintra, Desiree van Oorschot, Adriana Guzman-Holst

{"title":"Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia.","authors":"Ru Han, Ja Gomez, Cn Quy, Otavio Cintra, Desiree van Oorschot, Adriana Guzman-Holst","doi":"10.1080/14760584.2025.2523602","DOIUrl":"https://doi.org/10.1080/14760584.2025.2523602","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in adults ≥60 years. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modeled the burden of RSV among adults ≥60 years in India and Southeast Asia, and the potential impact of RSV vaccination.Methods: A Markov model was adapted to the settings of India, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. RSV ARI cases, LRTD-associated hospitalizations, pneumonia, and deaths were tallied over a five-year period. Impact of adjuvanted RSVPreF3 vaccination with 30% and 70% coverage was assessed by calculation of incremental differences versus no vaccination.Results: A total of 73.9 million RSV ARI were projected to occur in adults ≥60 years living in the selected countries. Numbers of hospitalizations, pneumonia, and deaths were approximately 3.1 million, 2.9 million, and 294,000, respectively. Adjuvanted RSVPreF3 vaccination with a 30% coverage could prevent 8.6 million RSV ARI, 460,255 hospitalizations, 423,659 pneumonia, and 43,693 deaths over five years.Conclusions: The projected burden of RSV was substantial in India and Southeast Asia, and could greatly be alleviated through adjuvanted RSVPreF3 vaccination of adults ≥60 years.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0